Expanded Criteria for Hepatocellular Carcinoma Through Down-Staging Prior to Liver Transplantation: Not Yet There

ABSTRACT

The accepted treatment strategy for hepatocellular carcinoma (HCC) is supported by randomized controlled trials (RCTs), meta-analysis, and large cohort studies. For instance, the Milan criteria applied for indicating liver transplantation have been validated by several cohort studies including more than 1000 patients. Regarding medical treatments, approximately 80 RCTs have been published so far in HCC. These studies provide the evidence to support chemoembolization as the treatment for patients at intermediate stage (meta-analysis of 6 RCTs) and show the lack of benefit of tamoxifen assessed in 12 RCTs including more than 1500 patients. In this scenario, what is the evidence to advocate for the expansion of HCC criteria through down-staging prior to liver transplantation? Such an approach has never been tested through RCTs or even well-designed cohort studies including enough patients and adequate follow-up. Only a few small studies with heterogeneous target populations and treatments applied are available. The results of these studies are inconsistent and do not provide compelling evidence to accept down-staging as a standard of care.

KEYWORDS

Hepatocellular carcinoma - liver transplantation - waiting list - down-staging - dropout - expansion of criteria

REFERENCES

• 1 Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002.  CA Cancer J Clin. 2005;  55 74-108
• 2 El Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med. 1999;  340 745-750
• 3 Sangiovanni A, Del Ninno E, Fasani P et al.. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.  Gastroenterology. 2004;  126 1005-1014
• 4 Mazzaferro V, Regalia E, Doci R et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med. 1996;  334 693-699
• 5 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362 1907-1917
• 6 Llovet J M, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.  Hepatology. 1999;  30 1434-1440
• 7 Llovet J M, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma.  Semin Liver Dis. 2005;  25 181-200
• 8 Roayaie S, Frischer J, Emre S H et al.. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 cm.  Ann Surg. 2002;  235 533-539
• 9 Bruix J, Sherman M. Management of hepatocellular carcinoma.  Hepatology. 2005;  42 1208-1236
• 10 Bruix J, Sherman M, Llovet J M et al.. Clinical management on hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference.  J Hepatol. 2001;  35 421-430
• 11 Llovet J M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival.  Hepatology. 2003;  37 429-442
• 12 Lopez P, Villanueva A, Llovet J M. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials.  Aliment Pharmacol Ther. 2006;  23 1535-1547
• 13 Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.  World J Surg. 1991;  15 270-285
• 14 Iwatsuki S, Starzl T E, Sheahan D G et al.. Hepatic resection versus transplantation for hepatocellular carcinoma.  Ann Surg. 1991;  214 221-229
• 15 Iwatsuki S, Gordon R D, Shaw B W, Starzl T E. Role of liver transplantation in cancer therapy.  Ann Surg. 1985;  202 401-407
• 16 Llovet J M, Bruix J, Fuster J et al.. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power.  Hepatology. 1998;  27 1572-1577
• 17 Bismuth H, Majno P E, Adam R. Liver transplantation for hepatocellular carcinoma.  Semin Liver Dis. 1999;  19 311-322
• 18 Jonas S, Bechstein W O, Steinmüller T et al.. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.  Hepatology. 2001;  33 1080-1086
• 19 Harnois D M, Steers J, Andrews J C et al.. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma.  Liver Transpl Surg. 1999;  5 192-199
• 20 Llovet J M, Real M I, Montaña X et al.. Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial.  Lancet. 2002;  359 1734-1739
• 21 Yao F Y, Bass N M, Nikolai B et al.. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.  Liver Transpl. 2003;  9 684-692
• 22 Maddala Y K, Stadheim L, Andrews J C et al.. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.  Liver Transpl. 2004;  10 449-455
• 23 Sharma P, Balan V, Hernandez J L et al.. Liver transplantation for hepatocellular carcinoma: the impact of MELD.  Liver Transpl. 2004;  10 36-41
• 24 Llovet J M, Sala M, Fuster J et al.. Predictors of drop-out and survival of patients with hepatocellular carcinoma candidates for liver transplantation.  Hepatology. 2003;  38 763A
• 25 Herrero J I, Sangro B, Quiroga J et al.. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma.  Liver Transpl. 2001;  7 631-636
• 26 Yao F Y, Ferrell L, Bass N M et al.. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.  Hepatology. 2001;  33 1394-1403
• 27 Marsh J W, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure?.  Liver Transpl. 2003;  9 693-696
• 28 Cillo U, Vitale A, Bassanello M et al.. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.  Ann Surg. 2004;  239 150-159
• 29 Burrel M, Llovet J M, Ayuso C et al.. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.  Hepatology. 2003;  38 1034-1042
• 30 Shetty K, Timmins K, Brensinger C et al.. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.  Liver Transpl. 2004;  10 911-918
• 31 Bruix J, Llovet J M. Prognostic prediction and treatment strategy in hepatocellular carcinoma.  Hepatology. 2002;  35 519-524
• 32 Majno P E, Adam R, Bismuth H et al.. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.  Ann Surg. 1997;  226 688-703
• 33 Yao F Y, Hirose R, LaBerge J M et al.. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.  Liver Transpl. 2005;  11 1505-1514
• 34 Mazzaferro V, Battiston C, Perrone S et al.. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study.  Ann Surg. 2004;  240 900-909
• 35 Graziadei I W, Sandmueller H, Waldenberger P. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.  Liver Transpl. 2003;  9 557-563
• 36 Majno P, Giostra E, Morel P, Hadengue A, Mentha G. Management of hepatocellular carcinoma in the waiting list before liver transplantation.  J Hepatol. 2005;  42(suppl 1) S134-S143
• 37 Oldhafer K J, Chavan A, Fruhauf N R et al.. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?.  J Hepatol. 1998;  29 953-959
• 38 Roayaie S, Llovet J M. Extended indications for liver transplantation in hepatocellular carcinoma.  Clin Liver Dis. 2005;  9 315-328
• 39 Llovet J M, Mas X, Aponte J J et al.. Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma before liver transplantation.  Gut. 2002;  50 123-128
• 40 Schwartz M. Liver transplantation for hepatocellular carcinoma.  Gastroenterology. 2004;  127 S268-S276
• 41 Molmenti E, Klintmalm G. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry.  Liver Transpl. 2002;  8 736-748